Translational Controversies: ADCs, Targeted Therapy, or Chemo?
Session Details
This session examines the evolving role of antibody-drug conjugates (ADCs) in breast cancer, debating whether they function primarily as targeted therapies or as chemotherapy, with insights from pathology and clinical evidence.
Moderator
David Rimm, Yale School of Medicine, New Haven, CT
Presentation numberCT1-01
HER2 low/ultralow: what the pathologist sees
Dennis Sgroi, Massachusetts General Hospital, Boston, MA
Presentation numberCT1-02
Evidence that ADCs are targeted therapy
Sarat Chandarlapaty, Memorial Sloan Kettering Cancer Center, New York, NY
Presentation numberCT1-03
Evidence that ADCs are chemotherapy
Sara A Hurvitz, Fred Hutchinson Cancer Center, Bellevue, WA